Some people strongly prefer avoiding injections, making Foundayo appealing
10.1186/1742-4682-5-8 35 RefsumH.YajnikC
Major trends in the forecast period include expansion of glp-1 therapies beyond diabetes, rising demand for long-acting and once-weekly formulations, growth of oral glp-1 receptor agonists, increasing focus on weight management indications, strategic partnerships and licensing agreements
Patent protection in the US lasts till 2031, so prices unlikely to drop much
NPI-001 has the potential to treat a broad set of diseases and conditions associated with oxidative stress and reduced glutathione levels such as slowing or stopping disease progression in retinitis pigmentosa patients with functional cones, regardless of their disease-causing genetic mutation
The JNK mechanism for acute analgesic tolerance was shared by buprenorphine and morphine-6-glucuronide (agonists that do not strongly recruit GRK-arrestin) but not by fentanyl or oxycodone